Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

4 treatments under study, led by Ertapenem

Research Leaders

13 sponsors active, led by Stiftung Forschung Infektionskrankheiten, Basel, Switzerland

Related Conditions

Often studied with 13 related conditions

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 27/100

Termination Rate

0.0%

0 terminated out of 4 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

2Total
Not Applicable (1)
Phase 4 (1)

Trial Status

Completed2
Suspended1
Unknown1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT03891433Phase 4Suspended

Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic UTI Due to -ESBL-producing Enterobacteriaceae

NCT02142933Not ApplicableCompleted

Simplified GBS Screening and Prevalence of ESBL in Pregnant Women

NCT01838213Completed

Extended Spectrum Betalactamase Producing Bacteria; Epidemiology and Treatment in Non-hospitalized Patients

NCT01208519Unknown

SATURN 04 Nosocomial Acquisition Study

Showing all 4 trials

Research Network

Common Treatments

  • Ertapenem1
  • Meropenem1
  • Vaginoperineal Swab1
  • Piperacillin Tazobactam 405g Solution For Injection1

Active Sponsors

  • Stiftung Forschung Infektionskrankheiten, Basel, Switzerland1
  • Clinical Centre of Serbia1
  • Universiteit Antwerpen1
  • Catholic University of the Sacred Heart1
  • University Hospital, Basel, Switzerland1

Top Investigators

Related Conditions

  • Carbapenem1
  • Urinary Tract Infection1
  • Environmental Contamination Of Esbl1
  • Clinical Trial1
  • Escherichia Coli Infection1

Activity Timeline